How Sotorasib works for advanced cancer

Sotorasib (Sotorasib) is an oral drug that targets the KRAS G12C mutation and is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with this mutation. This mutation is quite common in NSCLC and is associated with tumor development and drug resistance. Each patient's situation is different, and the effectiveness of sotoraxib may vary based on individual differences.

Current clinical trials show that sotorasiib has a certain therapeutic effect on patients with advanced NSCLC who have KRAS G12C mutation. In earlier studies, sotorasiib was found to cause tumors to shrink or stop growing, and it achieved sustained responses in some patients. In addition, the effect of the drug may also be affected by other factors, such as the characteristics of the tumor and the patient's overall health.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.